Rachel Neuwirth

Statistics

Publications

Citations

1.6K

H-Index

Active since

2001

Affiliations

Millennium Engineering and Integration (United States)(Current)

Takeda (United States)

Sarah Cannon

Dana-Farber Cancer Institute

Cornell University

Rachel Neuwirth is an author at Millennium Engineering and Integration (United States) specializing in medicine, bortezomib therapy, and pharmacology.

Publications per year

2001–2025

Publications

Analysis of Herpes Zoster Events Among Bortezomib-Treated Patients in the Phase III APEX Study

Asher Chanan‐Khan, Pieter Sonneveld, Michael W. Schuster et al. · Journal of Clinical Oncology · 2008 · 266 citations · Full text

Veterinary Medicine, Infectious Diseases, Pharmacotherapy +10

Efficacy and safety of bortezomib in patients with renal impairment: results from the APEX phase 3 study

Jesús F. San Miguel, Paul G. Richardson, Pieter Sonneveld et al. · Leukemia · 2008 · 184 citations

Pharmacy, Nephrology, Pharmacotherapy +14

Mutation of NRAS but not KRAS significantly reduces myeloma sensitivity to single-agent bortezomib therapy

George Mulligan, David I. Lichter, Alessandra Di Bacco et al. · Blood · 2013 · 117 citations · Full text

Medicine, Hematology, Oncology +14

Pharmacokinetic and pharmacodynamic study of two doses of bortezomib in patients with relapsed multiple myeloma

Donna Reece, Dan M. Sullivan, Sagar Lonial et al. · Cancer Chemotherapy and Pharmacology · 2010 · 107 citations · Full text

Medicine, Pharmacokinetics, Pharmacology +12

<scp>TAK</scp>‐228 (formerly <scp>MLN</scp>0128), an investigational oral dual <scp>TORC</scp>1/2 inhibitor: A phase I dose escalation study in patients with relapsed or refractory multiple myeloma, non‐Hodgkin lymphoma, or Waldenström's macroglobulinemia

Irene M. Ghobrial, David S. Siegel, Ravi Vij et al. · American Journal of Hematology · 2016 · 94 citations · Full text

Medicine, Pharmacology, Pharmacotherapy +17

1–5 of 29